Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Science in Society

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed Kaleem Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean-Charles Soria and Gypsyamber D'Souza; for the AACR COVID-19 and Cancer Task Force
Antoni Ribas
1Department of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aribas@mednet.ucla.edu
Rajarshi Sengupta
2American Association for Cancer Research, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trevan Locke
2American Association for Cancer Research, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sayyed Kaleem Zaidi
2American Association for Cancer Research, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katie M. Campbell
1Department of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katie M. Campbell
John M. Carethers
3Departments of Internal Medicine and Human Genetics and Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John M. Carethers
Elizabeth M. Jaffee
4Department of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth M. Jaffee
E. John Wherry
5Department of Systems Pharmacology and Translational Therapeutics, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Charles Soria
6Paris Saclay University, Saint-Aubin, France and Drug Development Department, Gustave Roussy, Villejuif, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gypsyamber D'Souza
7Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gypsyamber D'Souza
DOI: 10.1158/2159-8290.CD-20-1817 Published February 2021
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Scatter plot of COVID-19–related CFRs from series comparing rates from patients with cancer (red dots) with patients without cancer (gray dots). [Series includes publications from Sng et al. (2); Cattaneo et al. (7); Meng et al. (9); Mehta et al. (11); Brar et al. (6); Ruthrich et al. (4); Lunski et al. (5); Tian et al. (10); Wang et al. (3); and Dai et al. (12)].

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Forest plot of series reporting hazard ratios (HR; top in red) or odds ratios (OR; bottom in blue) for death, or severity of COVID-19 in the case of the Tian series, in patients with COVID-19 and cancer compared with no cancer. The size of the symbol is proportional to the number of individuals in each series. The line represents the lower and upper limits of the 95% confidence intervals. Negative HR or OR values favor decreased risk for death, whereas positive values represent increased risk for death or severity of COVID-19. [Series includes publications from Meng et al. (9); Williamson et al. (8); Mehta et al. (11); Williamson et al. (8); Sng et al. (2); Brar et al. (6); Tian et al. (10); Dai et al. (12); and Lunski et al. (5)].

Additional Files

  • Figures
  • Supplementary Data

    • Tables S1-S4 - Supplemental Table S1. Studies comparing outcomes among SARS-COV-2 infected patients with cancer and those without cancer. Supplemental Table S2. Studies comparing outcomes among SARS-COV-2 infected patients with cancer and uninfected patients with cancer Supplemental Table S3. Studies reporting outcomes among SARS-COV-2 infected patients with cancer without any comparison Supplemental Table S4. Metanalyses of published studies on COVID-19-cancer connection
    • AACR COVID-19 and Cancer Task Force - AACR COVID-19 and Cancer Task Force
    • AACR COVID-19 and Cancer Task Force Bios - AACR COVID-19 and Cancer Task Force Bios
PreviousNext
Back to top
Cancer Discovery: 11 (2)
February 2021
Volume 11, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed Kaleem Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean-Charles Soria and Gypsyamber D'Souza for the AACR COVID-19 and Cancer Task Force
Cancer Discov February 1 2021 (11) (2) 233-236; DOI: 10.1158/2159-8290.CD-20-1817

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed Kaleem Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean-Charles Soria and Gypsyamber D'Souza for the AACR COVID-19 and Cancer Task Force
Cancer Discov February 1 2021 (11) (2) 233-236; DOI: 10.1158/2159-8290.CD-20-1817
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Authors' Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Black in Cancer: Championing Diversity in Cancer Research and Medicine
  • The Race toward Equity: Increasing Racial Diversity in Cancer Research and Cancer Care
Show more Science in Society
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement